Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals only.
      BOTOX® (botulinum toxin type A) Prescribing Information and adverse event reporting information can be found below.

      NDO D 2
      NDO M 2

      UK-BUO-250027. DOP: May 2025.

      Understanding and addressing the unmet need in urology: Neurogenic Detrusor Overactivity (NDO)

      Prevalence of NDO

      Spinal lesions caused by trauma, such as spinal cord injury, or by a progressive neurological condition, such as multiple sclerosis can lead to NDO.

      NDO is a complex, multi-symptom syndrome that can be difficult to treat, requiring appropriate effective management - including treatment or referrals to improve patient outcomes

      The aetiology of NDO10,11

      Aetiologies

      • Spinal cord injury
      • Spina bifida
      • Multiple sclerosis
      • Stroke
      • Parkinson’s disease
      • Cerebrovascular accidents
      • Other

      Common bladder storage symptoms and definitions11,12

      Table 2

      Consequences of untreated NDO13-15

      X1470 NDO UK BOTOX Sales Aid - New Branding_4 1

      Adapted from Tubaro, 2004.13

      NDO is a complex, multi-symptom syndrome that can be difficult to treat, requiring appropriate effective management - including treatment or referrals to improve patient outcomes

      MS, multiple sclerosis; NDO, neurogenic detrusor overactivity; QoL: quality of life; SCI, spinal cord injury.

      DIAGNOSING NDO

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Aspire News. Spinal cord injury. Available at: https://www.aspire.org.uk/news/every-four-hours. Accessed June 2025.
      7. Ginsberg D. The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care. 2013;19:S191-S196
      8. Litwiller S E, Frohman E M and Zimmern P E. Multiple sclerosis and the urologist. J Urol. 1999;161:743–757
      9. MS Society. MS Prevalence Report January 2020. Available at: https://www.mssociety.org.uk/. Accessed June 2025.
      10. Abrams P et al. Incontinence: 6th Edition 2017;50
      11. Blok B, et al. EAU Guidelines on Neuro-Urology. 2025. Available at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Neuro-Urology-2025.pdf. Accessed June 2025.
      12. Castro Diaz D, Robinson D et al. Patient-reported Outcome Assessment. Abrams P et al. Incontinence: 6th Edition. 2017:50
      13. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(suppl 6A);2–6
      14. de Seze M, Ruffion A et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Multiple Sclerosis. 2007;13:915–928
      15. Goldmark E, Niver B and Ginsberg D A. Neurogenic bladder: from diagnosis to management. Curr Urol Rep. 2014;15:448

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Aspire News. Spinal cord injury. Available at: https://www.aspire.org.uk/news/every-four-hours. Accessed June 2025.
      7. Ginsberg D. The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care. 2013;19:S191-S196
      8. Litwiller S E, Frohman E M and Zimmern P E. Multiple sclerosis and the urologist. J Urol. 1999;161:743–757
      9. MS Society. MS Prevalence Report January 2020. Available at: https://www.mssociety.org.uk/. Accessed June 2025.
      10. Abrams P et al. Incontinence: 6th Edition 2017;50
      11. Blok B, et al. EAU Guidelines on Neuro-Urology. 2025. Available at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Neuro-Urology-2025.pdf. Accessed June 2025.
      12. Castro Diaz D, Robinson D et al. Patient-reported Outcome Assessment. Abrams P et al. Incontinence: 6th Edition. 2017:50
      13. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(suppl 6A);2–6
      14. de Seze M, Ruffion A et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Multiple Sclerosis. 2007;13:915–928
      15. Goldmark E, Niver B and Ginsberg D A. Neurogenic bladder: from diagnosis to management. Curr Urol Rep. 2014;15:448

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The BOTOX® Summary of Product Characteristics can be found here

      BOTOX® PRESCRIBING INFORMATION

      By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: June 2025. UK-BUO-250049.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-250217. Date of preparation June 2025. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.